We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma
Read MoreHide Full Article
Bristol Myers Squibb (BMY - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending the approval of chimeric antigen receptor (CAR) T cell immunotherapy, Abecma.
The committee recommended granting Conditional Marketing Authorization to Abecma (idecabtagene vicleucel; ide-cel), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
The European Commission (EC) will take the recommendation into account while reviewing the application but is not bound by it.
The EC is expected to give a final decision within 67 days of the receipt of the CHMP opinion.
Abecma, a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy, is approved in the United States for the treatment of adult patients with relapsed or refractory multiple myeloma.
It is being developed in collaboration with bluebird bio (BLUE - Free Report) .
Concurrently, the CHMP also recommended the approval of blockbuster immuno-oncology drug, Opdivo (nivolumab), for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).
The positive opinion is based on encouraging results from the phase III CheckMate -577 study.
It is approved in the United States for the adjuvant treatment of completely resected esophageal or GEJ cancer with residual pathologic disease in patients who have received neoadjuvant CRT.
Shares of Bristol Myers have gained 7.1% so far this year compared with the industry’s growth of 0.5%.
Image Source: Zacks Investment Research
Approval of additional indications should boost Opdivo sales. The company’s performance in the first quarter of 2021 was dismal as Opdivo’s sales declined facing stiff competition from the likes of Merck’s (MRK - Free Report) Keytruda. Moreover, Revlimid sales weren’t impressive.
Nevertheless, the recent approval of new drugs adds a stream of revenues, which should propel growth in the coming quarters.
Last month, the FDA gave a nod to Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately-to-severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
The EC has granted full Marketing Authorization to Onureg (azacitidine tablets) as a maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed, hematopoietic stem cell transplantation (HSCT).
Repligen’s earnings estimates for 2021 have increased to $2.26 from $1.91 in the past 60 days. The stock price has increased 1.7% in the year so far.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Bigstock
Bristol Myers (BMY) Gets Positive CHMP Opinion for Abecma
Bristol Myers Squibb (BMY - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion recommending the approval of chimeric antigen receptor (CAR) T cell immunotherapy, Abecma.
The committee recommended granting Conditional Marketing Authorization to Abecma (idecabtagene vicleucel; ide-cel), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
The European Commission (EC) will take the recommendation into account while reviewing the application but is not bound by it.
The EC is expected to give a final decision within 67 days of the receipt of the CHMP opinion.
Abecma, a B-cell maturation antigen (BCMA)-directed genetically modified autologous T cell immunotherapy, is approved in the United States for the treatment of adult patients with relapsed or refractory multiple myeloma.
It is being developed in collaboration with bluebird bio (BLUE - Free Report) .
Concurrently, the CHMP also recommended the approval of blockbuster immuno-oncology drug, Opdivo (nivolumab), for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).
The positive opinion is based on encouraging results from the phase III CheckMate -577 study.
It is approved in the United States for the adjuvant treatment of completely resected esophageal or GEJ cancer with residual pathologic disease in patients who have received neoadjuvant CRT.
Shares of Bristol Myers have gained 7.1% so far this year compared with the industry’s growth of 0.5%.
Approval of additional indications should boost Opdivo sales. The company’s performance in the first quarter of 2021 was dismal as Opdivo’s sales declined facing stiff competition from the likes of Merck’s (MRK - Free Report) Keytruda. Moreover, Revlimid sales weren’t impressive.
Nevertheless, the recent approval of new drugs adds a stream of revenues, which should propel growth in the coming quarters.
Last month, the FDA gave a nod to Zeposia (ozanimod) 0.92 mg for the treatment of adults with moderately-to-severely active ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD).
The EC has granted full Marketing Authorization to Onureg (azacitidine tablets) as a maintenance therapy in adult patients with acute myeloid leukemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed, hematopoietic stem cell transplantation (HSCT).
Bristol-Myers currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the health care sector is Repligen Corporation (RGEN - Free Report) , which presently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Repligen’s earnings estimates for 2021 have increased to $2.26 from $1.91 in the past 60 days. The stock price has increased 1.7% in the year so far.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>